ADAR 抗体
Quick Overview for ADAR 抗体 (ABIN6942050)
抗原
See all ADAR 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
交叉反应
- 人
-
交叉反应 （详细）
- WB(1:500-2000), IF(ICC)(1:50-200), IHC-P(1:50-200), IF(IHC-P)(1:50-200)
-
纯化方法
- Purified by Protein A.
-
免疫原
- Recombinant protein within human ADAR1 aa 100-300
-
亚型
- IgG
-
-
anti-Adenosine Deaminase, RNA-Specific (ADAR) (AA 1-1226) antibody
ADAR 适用: 人 WB, IF, IHC (p) 宿主: 小鼠 Polyclonal unconjugated
anti-Adenosine Deaminase, RNA-Specific (ADAR) (AA 150-250) antibodyADAR 适用: 人 WB, IHC 宿主: 兔 Polyclonal unconjugated
anti-Adenosine Deaminase, RNA-Specific (ADAR) antibodyKO Validated ADAR 适用: 人 WB, IF, IP, IHC (p), ICC 宿主: 兔 Polyclonal unconjugated
anti-Adenosine Deaminase, RNA-Specific (ADAR) (AA 1085-1223) antibodyADAR 适用: 人 ELISA, ICC, FACS 宿主: 小鼠 Monoclonal 4E2E4 unconjugated
anti-Adenosine Deaminase, RNA-Specific (ADAR) (AA 1-1226) antibodyADAR 适用: 人 WB, IF, IP 宿主: 兔 Polyclonal unconjugated
anti-Adenosine Deaminase, RNA-Specific (ADAR) (AA 1085-1223) antibodyADAR 适用: 人 WB, ELISA, FACS 宿主: 小鼠 Monoclonal 4E2B5 unconjugated
anti-Adenosine Deaminase, RNA-Specific (ADAR) (AA 151-250) antibodyADAR 适用: 人 WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro) 宿主: 兔 Polyclonal unconjugated
anti-Adenosine Deaminase, RNA-Specific (ADAR) (AA 367-471) antibodyADAR 适用: 人 WB, IHC, ELISA 宿主: 兔 Polyclonal unconjugated
anti-Adenosine Deaminase, RNA-Specific (ADAR) (N-Term) antibodyADAR 适用: 人 WB, IHC 宿主: 兔 Polyclonal unconjugated
anti-Adenosine Deaminase, RNA-Specific (ADAR) (C-Term) antibodyADAR 适用: 人, 小鼠, 大鼠, 豚鼠, 马, 兔 WB, IHC 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
-
WB 1:300-5000
IHC-P 1:200-400
IF(IHC-P) 1:50-200
IF(ICC) 1:50-200 -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- Aqueous buffered solution containing 1xTBS ( pH 7.4), 1 % BSA, 40 %Glycerol and 0.05 % Sodium Azide.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Store at 4°C for up to 2 weeks. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
有效期
- 12 months
-
-
- ADAR (Adenosine Deaminase, RNA-Specific (ADAR))
-
别名
- ADAR
-
背景
-
Synonyms: Double-stranded RNA-specific adenosine deaminase, 136 kDa double-stranded RNA-binding protein, Interferon-inducible protein 4, K88DSRBP, DRADA, p136, IFI-4, ADAR, ADAR1, DSRAD, G1P1, IFI4.
Background: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence.
-
基因ID
- 103
-
UniProt
- P55265
-
途径
- Protein targeting to Nucleus
抗原
-
